APC Platform Optimizing B Cell Activation and Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for enhancing antigen presentation and immune responses are limited, particularly in activating B cells for effective antitumor and infectious disease therapies, as they often require co-culture with transfected cell lines or do not induce optimal activation.
Innovation Solution
A platform comprising cytokines such as Flt-3L and GM-CSF, along with adjuvants like EDAC, CHX, and α-GalCer, is used to enhance the effectiveness of antigen-presenting cells (APCs) by loading them with antigens and adjuvants, thereby boosting immune responses in vivo.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If B cells are activated using TLR ligands, then B cell activation is induced, but optimal activation is not achieved
Solution Approach 1:
The patent changes the parameters of B cell activation by combining multiple stimuli (anti-CD40 antibodies, TLR ligands, and cytokines like Flt3-L and IL-3) rather than using a single stimulus. This multi-parameter approach achieves optimal activation that cannot be obtained with TLR ligands alone, resolving the contradiction between reliability of activation and level of activation achieved.
2Reliability
If B cells are co-cultured with transfected cell lines expressing CD40L, then B cell activation is achieved, but the method is complex and less suitable for clinical application
Solution Approach 1:
The patent extracts the essential activation signal (CD40L function) from the complex transfected cell line system and delivers it directly through anti-CD40 antibodies. This simplifies the activation method by removing the need for co-culture with engineered cell lines while maintaining reliable B cell activation, thus resolving the contradiction between activation reliability and system complexity.
Solution Approach 2:
The patent uses anti-CD40 antibodies as an intermediary molecule to transfer the activation signal to B cells. Instead of requiring direct cell-to-cell contact with CD40L-expressing cells, the antibody serves as a soluble mediator that binds to CD40 on B cells and delivers the activation signal, simplifying the system while maintaining effectiveness.
3Productivity
If Flt-3L dosage is increased to enhance DC maturation, then immune response is boosted, but the dosage is limited to 8 μg/kg or less to avoid adverse effects
Solution Approach 1:
The patent combines Flt-3L with other cytokines (particularly GM-CSF and IL-3) and adjuvants to achieve synergistic effects. This combination allows for enhanced DC maturation and immune response at lower, safer doses of Flt-3L, resolving the contradiction between productivity enhancement and avoidance of harmful effects by distributing the immunostimulatory function across multiple agents.
Data Source
AI summary
Disclosed herein are methods and platforms for increasing utility and efficacy of a cellular vaccine. Specifically, disclosed are steps that optimize ex vivo B cell expansion and boost host in vivo immunity. Also disclosed is a platform for enhancing effectiveness of antigen presentation and antigen-specific immune responses. Also disclosed is a method for enhancing effectiveness of APCs in a subject. Also disclosed are vaccines and kits based on the platform.